DEF: Cardio Diagnostics Seeks Shareholder Approval for Capital Raise, Director Elections

Cardio Diagnostics Holdings, Inc. is holding its annual meeting on October 15, 2025, seeking stockholder approval for director elections, a significant future share issuance to raise capital, and auditor ratification.

Summary

• The Annual Meeting of Stockholders will be held virtually on October 15, 2025, at 10:00 a.m. Central Time.
• Stockholders will vote on the election of seven director nominees to serve for a one-year term.
• Approval is sought for the future issuance of shares of common stock and/or convertible securities equal to 20% or more of common stock outstanding in non-public transactions, up to an aggregate of $10.0 million and 1,666,666 shares (post 1-for-30 reverse stock split), with a maximum discount of 25%.
• Stockholders will also vote on the ratification of Prager Metis CPAs LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• As of August 25, 2025, there were 1,763,129 shares of common stock outstanding and entitled to vote.
• The company has already raised approximately $14.8 million by issuing 1,054,841 shares under an At-the-Market (ATM) Offering Agreement in 2024 and 2025.

Sentiment

Score: 4

Explanation: The company is actively addressing its capital needs and maintaining corporate governance, which are positive. However, the explicit need for significant capital due to a low stock price and the potential for substantial dilution indicate underlying financial challenges, leading to a cautious sentiment.

Positives

• The company is proactively seeking stockholder approval to maintain flexibility for future capital raising, which is crucial for ongoing operations.
• A robust corporate governance framework is in place, including independent directors on the Audit, Compensation, and Nominating and Corporate Governance Committees.
• The Board of Directors and executive team possess diverse and relevant expertise in medicine, engineering, artificial intelligence, cybersecurity, finance, and public markets.
• The company has adopted a Compensation Recovery (Clawback) Policy and a strict prohibition on hedging or pledging company stock, aligning with strong governance practices.
• The Audit Committee has a designated financial expert, Paul F. Burton, ensuring competent oversight of financial reporting.

Negatives

• The company explicitly states a continued need to raise additional capital to maintain operations and meet short-term liquidity requirements.
• The low trading price of common stock is a significant factor necessitating the potential issuance of a substantial number of shares, which could lead to considerable dilution for existing stockholders.
• The proposed future share issuance could have an anti-takeover effect and potentially concentrate voting power in the hands of a few large investors.

Risks

• Inability to raise additional capital may make it difficult to continue current operations and could necessitate adjustments to the business plan.
• The future issuance of common stock or convertible securities will dilute existing stockholders' proportionate ownership and could negatively impact book value per share and future earnings per share.
• The sale or resale of newly issued shares could cause prevailing market prices of common stock to decline.
• Future issuances could concentrate voting power in the hands of a few stockholders, potentially influencing company operations or voting outcomes.
• The company's status as an 'emerging growth company' allows for exemptions from certain reporting requirements, which may result in less comprehensive information for stockholders compared to other public companies.
• A potential conflict of interest exists with Warren Hosseinion, Non-Executive Chairman, due to his 10% ownership in Altitude Capital Group LLC, which served as a placement agent for a Private Placement, although policies are in place to mitigate this.
• Dr. Robert Philibert's personal epigenetic developments, unrelated to the company's current mission, are his sole property and not assigned to the company, potentially limiting future product expansion.

Future Outlook

The company needs to raise additional capital to maintain operations and meet short-term liquidity requirements. It is seeking stockholder approval for flexibility to raise up to $10.0 million through non-public transactions, potentially involving significant share issuance. The Board will continue to consider all strategic alternatives, including additional debt or equity capital, asset disposal, and other strategic transactions or restructuring measures.

Management Comments

• "Your vote is important. Please vote as soon as possible by one of the methods shown above." Meeshanthini V. Dogan, Chief Executive Officer
• "Our Board of Directors has determined that it is in the best interests of our company and our stockholders to maintain the flexibility of having an alternative means to raise capital, separate from the ATM Agreement."
• "Because the trading price of our Common Stock remains low, the same factors that gave rise to the Prior Securities Issuance Proposals are still relevant."
• "We continue to need to raise additional capital to maintain our operations and meet our short-term liquidity requirements. If we cannot raise additional capital, we may find it difficult to continue our current operations, resulting in a need to adjust our current business plan."

Industry Context

Cardio Diagnostics Holdings, Inc. operates in the cardiovascular diagnostics sector, utilizing AI/machine learning-driven genetic-epigenetic approaches. The company's need for capital and reliance on various financing mechanisms, including At-the-Market offerings and proposed non-public transactions, is characteristic of many early-stage or growth-phase biotech and medtech companies that require substantial funding for research, development, and commercialization before achieving consistent profitability. The virtual format for the annual meeting aligns with modern corporate practices for broader stakeholder engagement.

Comparison to Industry Standards

• The company's strategy of seeking approval for dilutive capital raises, such as the proposed $10.0 million issuance, is a common practice for small-cap biotech/medtech firms, particularly those with novel diagnostic technologies that are pre-profitability or in expansion phases, similar to peers like Guardant Health or Natera in their earlier stages.
• The maximum 25% discount to market for future non-public transactions is within the typical range observed in the industry for such capital raises, reflecting the balance between attracting investors and minimizing dilution under prevailing market conditions.
• The board's composition, which includes medical professionals (Dr. Dogan, Dr. Philibert, Dr. Hosseinion, Dr. Fung) alongside finance and cybersecurity experts (Ms. Betts, Mr. Burton, Mr. Intrater), aligns with best practices for health technology companies, ensuring a blend of scientific acumen and robust corporate oversight, comparable to boards of companies like Exact Sciences or Invitae.
• The adoption of a Compensation Recovery (Clawback) Policy and a prohibition on hedging/pledging company stock demonstrates adherence to evolving corporate governance standards, mirroring practices seen in more mature public companies and reflecting increased regulatory scrutiny post-Sarbanes-Oxley.

Management Changes

Corporate Governance

Related Party Transactions

• Meeshanthini Dogan and Robert Philibert, co-founders, benefit from an exclusive, worldwide patent license of the Core Technology from the University of Iowa Research Foundation (UIRF), as inventors are generally entitled to 25% of income from their inventions.
• Warren Hosseinion, Non-Executive Chairman, holds a 10% ownership interest in Altitude Capital Group LLC, which served as the Placement Agent for the company's Private Placement. This creates a potential conflict of interest, though policies are in place to mitigate it, and Dr. Hosseinion received no compensation for the Private Placement.
• Dr. Robert Philibert's personal epigenetic developments, unrelated to the company's current mission, are his sole property and not assigned to the company, with their use at his sole discretion.

Stakeholder Impact

• **Shareholders**: Face potential significant dilution from the proposed future share issuance, but also stand to benefit from the company securing necessary capital for continued operations and strategic growth. They have a direct say in key governance matters and the capital raise through their votes.
• **Employees**: Benefit from the company's efforts to secure liquidity, which supports ongoing operations and job stability. They participate in 401(k) and health/welfare plans, and executive compensation includes equity incentive awards.
• **Management**: Their compensation packages are detailed, and they are subject to a Clawback Policy, increasing accountability. The capital raise is critical for their ability to execute the business plan.
• **Creditors**: The successful execution of capital raises could improve the company's liquidity position, enhancing its ability to meet short-term obligations.
• **Customers**: Continued operations and potential for further product development, enabled by successful capital raising, could lead to enhanced or new cardiovascular diagnostic solutions.

Next Steps

• Stockholders are urged to vote on the election of directors, the future share issuance proposal, and the auditor ratification at the Annual Meeting on October 15, 2025.
• If Proposal No. 2 is approved, the company may proceed with non-public capital raising transactions within three to six months.
• Final voting results from the Annual Meeting will be published in a Current Report on Form 8-K within four business days.
• Stockholders wishing to present proposals for inclusion in the 2026 Annual Meeting proxy statement must submit them by May 7, 2026.
• Other stockholder proposals or director nominations for the 2026 Annual Meeting must be received between June 17, 2026, and July 17, 2026, as per company Bylaws.

Key Dates

Recommendation

While the company is proactively addressing its capital needs and has a strong governance structure, the explicit need for significant capital due to a low stock price and the potential for substantial dilution present considerable risks. The future capital raise, if successful, could stabilize operations but also dilute existing shareholder value. Investors should hold to monitor the execution of the capital raise and its impact on the company's financial health and stock performance.

Keywords

Cardio Diagnostics, Proxy Statement, Annual Meeting, Capital Raise, Share Issuance, Director Election, Auditor Ratification, Corporate Governance, Nasdaq Listing Rule 5635(d), Equity Incentive Plan, Executive Compensation, Risk Management, Cardiovascular Diagnostics, Epigenetics, Biomedical Engineering